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Abstract
Current schemes used to serotype Vibrio vulnificus are based
on direct bacterial agglutination using polyclonal rabbit
antisera.

During the course of serotyping Louisiana V.

vulnificus isolates we failed to observe a reproducible
agglutination profile for these isolates.

The major

obstacle in producing serovar specific sera has been the
failure to produce high titered anti-LPS sera in rabbits.
Anti-LPS serum from rabbits immunized with formalin-killed,
heat-killed, or acetone dried whole cell vaccines and LPScarrier conjugates uniformly produced titers < 320.
Separation of anti-LPS activity from whole sera by affinity
chromatography also yielded low titered antisera.

A typing

system predicated on the detection of LPS-associated O
antigens using monoclonal antibodies (Mab) is proposed for
V. vulnificus.

Hybridomas have been established which

produce antibodies that react with LPS purified from
vulnificus. V. damsela. and V. hollisae.

V.

Vibrio vulnificus

shows considerable heterogeneity within the genus.

Twenty-

four Mabs produced to date, react with 10 of 16 (61%) of V.
vulnificus strains tested by LPS ELISA.

Monoclonal

antibodies react more strongly with the translucent than the
opaque phenotype o'f V. vulnificus using whole cell ELISA.
Monoclonal antibodies reactive by LPS ELISA with V. damsela
and V. hollisae LPS are non-reactive with LPS prepared from
V. vulnificus.

Introduction
In recent years there has been a dramatic increase in
the incidence of fulminate infections caused by Vibrio
vulnificus.

Since these infections may be rapidly fatal,

prompt diagnosis and treatment are essential.

Of equal

importance is the monitoring of both the marine environment
and seafood to reduce the risk of infection.
Organisms belonging to the genus Vibrio have been known
to cause disease in humans for many years.

Vibrio cholerae.

the etiologic agent of classical Asiatic cholera, was among
the first enteric pathogens to be isolated and
characterized.

Due to the extreme virulence and wide

distribution of V. cholerae in nature,

it has historically

been the most thoroughly studied member of the genus V i brio.
As serological studies of V. cholerae became possible,
the members of the genus Vibrio which did not type in V.
cholerae typing sera (0-Group 1 or Group 01's) were
dismissed as "non-agglutinable vibrios"
cholera vibrios"
1985).

(NCV's)

(NAG's) or as "non

(Blake et al. 1980; Farmer et al.

The grouping of vibrios into such a category, based

on the absence of a serological reaction, was unsatis
factory.

The reports of human infection caused by halo-

philic non-cholerae Vibrios continued to accumulate in the
literature (Blake et al. 1980).

Several different Vibrio

species have been identified among these pathogenic noncholerae vibrios.

In addition to being distinct biological
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entities, these organisms were found to have unique
pathogenic properties.

At the present time, ten species in

the genus Vibrio have been isolated from clinical specimens
(Table 1).
In the early 1970's there were numerous reports of a
non-cholera Vibrio that was associated with sepsis and softtissue infections (Roland 1970; Zide et al. 1974;
Thorsteinsson et al. 1974; Fernandez and Pankey 1975; Hollis
et al. 1976).

These infections were characterized by either

primary septicemia or intense local tissue swelling followed
by necrosis in infected wounds.

This pattern of soft tissue

destruction or primary septicemia was strikingly different
from the gastroenteritis and diarrhea seen with V. cholerae
or V. parahaemolvticus (Roland 1970; Zide et al. 1974;
Thorsteinsson et al. 1974; Fernandez and Pankey 1975; Hollis
et al. 1976)(Table 1).
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TABLE 1.

Vibrio species isolated from clinical specimens

and their most common associated diseases.

Oraanism

Disease (s)

V. alcrinolvticus

Wound infection, otitis

V. cholerae

Gastroenteritis

V. damsela

Wound infection,septicemia

V. fluvialis

Gastroenteritis

V. furnissii

Gastroenteritis

V. hollisae

Gastroenteritis, septicemia

V. metschnikovii

Rare; urine, blood

V. mimicus

Gastroenteritis, otitis

V. oarahaemolvticus

Gastroenteritis, wound inf.

V. vulnificus

Wound infection,

septicemia
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This new organism was at first thought to be a variant
of V. parahaemolvticus

(Roland 1970? Zide et al. 1974).

Upon closer scrutiny it was found to have several unique
characteristics, the most obvious of these was the ability
to ferment lactose.

These organisms were found to be ONPG

positive (produce B-galactosidase)

75% of the time compared

to V. parahaemolvticus. which is positive only 5% of the
time (Farmer et al. 1985).

The capacity to ferment lactose

led to these isolates being referred as the L+ Vibrios
(Hollis et al. 1976).
The incidence of L+ Vibrio associated disease began to
rise as this organism was recognized as a distinct pathogen.
By 1980 reports of L+ Vibrio infections from the United
States, Japan, Belgium, and Australia had established L+
Vibrios as a pathogen, and had brought the name V.
vulnificus into widespread use (Matsuo et al. 1978; Mertens
et al. 1979; Ghosh and Bowen 1980).

Briefly,

(1970-1976) V.

vulnificus was referred to as a variant of V.
parahaemolvticus (Roland 1970; Zide et al.,1974).

By 1976,

these Lac (+) organisms were recognized as a new species and
(1976-1979) were assigned to the genus Beneckae as Beneckea
vulnifica (Reichelt et al. 1976).

Farmer (1979) proposed

that the organism be reassigned to the genus Vibrio as
Vibrio vulnificus in 1979, and that designation has been
accepted by most workers.

By 1979, Blake et al.

(1980)

reported that 41 V. vulnificus infections had been described
in the literature.
Vibrio vulnificus is widely distributed in the marine
environment.

Oliver et al.

environmental studies.

(1982, 1983) have done extensive

Their studies have shown that Vibrio

species account for 26% to 30% of all bacteria isolated.

A

very small proportion of these vibrios were identified as V.
vulnificus.

Of all the Vibrio isolates that Oliver et a l .

recovered, only 4.2% fermented lactose, and of the Lac (+)
isolates only 20% were identified to the species level as V.
vulnificus.

Vibrio vulnificus was most commonly isolated

from animals (84% from clams), and 82% of these isolates
were found to be pathogenic for mice.

These data were

obtained from 80 collection sites which ranged from Maine to
Florida on the Atlantic coast (Oliver et al. 1982; Oliver et
al. 1983).

A survey of west coast estuaries in 1984

correlated with the east coast data in that V. vulnificus
was isolated from 6% of the water specimens (Kaysner et al.
1987) .

Both studies concluded that V. vulnificus was

present in very low numbers in each of the marine sites
teste d .
The presence of V. vulnificus in the marine environment
is dependent on the water temperature and salinity.

A study

by Kelly (1982) has shown that over a 12 month period V.
vulnificus was found to be most often isolated from areas of
low salinity during the warmer months of the year (May
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through October).

Vibrio vulnificus has a growth

temperature optimum of 37° C.

Studies have shown that

V.

vulnificus was isolated most frequently in the water along
the Gulf Coast during the summer months when temperatures
consistently remain above 25° C.

In a study of the recovery

rate for V. vulnificus 100% of Galveston Island sites were
positive for V. vulnificus in September, however, by
December all of these site were negative for V. vulnificus
(Kelly, 1982).
Historically oysters were not harvested during the
summer months.

In recent years, however, oysters and other

seafood have been harvested on a year-round basis.
Harvesting oysters during the summer months, when the water
from which they are being taken contains the highest
concentration of V. vulnificus, increases human exposure to
V. vulnificus.

Since outbreaks of foodborne vibriosis in

humans follow consumption of raw oysters or other seafood
harvested from the Gulf Coast it has been inferred that this
change in harvesting is responsible for the increase in V.
vulnificus infection.

The recent recognition of V.

vulnificus as an important human pathogen demonstrates that
the balance between health and disease can be drastically
altered by seemingly small changes in the way man interacts
with his environment.
Oysters are filter feeders that concentrate food
material from seawater.

Kelly and Dinuzzo (1985) showed
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that V. vulnificus was concentrated by oysters when they
were exposed to water inoculated with V. vulnificus.

When

V. vulnificus was removed from the water the oysters rapidly
cleared their V. vulnificus burden.

These findings suggest

that oysters may become reservoirs for V. vulnificus in
contaminated waters but, that V. vulnificus may not be
growing within the oyster (Kelly and Dinuzzo,

1985).

Presently, the process of depuration is being investigated
as a method of sanitizing oysters.
There is no apparent difference between environmental
and clinical isolates when biochemical characteristics or
antibiotic susceptibility profiles are compared (Johnson and
Calia 1981; Tison and Kelly 1986).

Genetic studies revealed

that clinical and environmental isolates of V. vulnificus
have a base composition of 47-48 mol% guanine + cytosine and
share > 85% DNA homology by hybridization (Tison and Siedler
1981).
Although V. vulnificus infections have been documented
in the literature since the early 1970's, it was not until
the mid- 1980's that these infections received public
attention.

Blake (1983) urged persons with liver disease or

immunologic disorders to abstain from eating raw seafood.
In April of 1985, the Food and Drug Administration (FDA)
published a warning to patients with liver disease and other
chronic diseases about V. vulnificus infections (FDA Drug
Bulletin 1985).

It is unclear whether the increase in

reported V. vulnificus infections during the last two years
represents an actual increase in incidence or an increase in
the recognition and reporting of these infections.
Disease produced by V. vulnificus usually falls into
one of two categories, a local dermal infection at the site
of an injury (puncture wound) or a disseminated primary
septicemia.

The majority of V. vulnificus infections

involve exposure to seawater or raw seafood (Blake 1979;
Bonner 1983; Johnston 1985).

However, several cases have

been reported where the infection was acquired in inland
areas, and no contact with the marine environment could be
established (Mertens et al. 1979; Tacket 1984).

These

inland isolates were recovered from waters with salinity
levels sufficient to support the growth of V. vulnificus.
Among Vibrio pathogens, the production of skin lesions
and primary septicemia is relatively infrequent.

V.

parahaemolvticus and V. cholerae Non-01 may produce wound
infections and septicemias, however, they most commonly
produce gastroenteritis (Farmer et al. 1985).

A recently

recognized V i brio. V. hollisae.' causes severe diarrhea.
However, cases of V. hollisae bacteremia have been reported
(Morris et al. 1982; Farmer 1985; Rank et al. 1988).

In one

instance, V. hollisae produced a bacteremia in a patient
with chronic active hepatitis.
dried, salted fish.

This patient had eaten

However, V. hollisae could not be

recovered from fish purchased at the same store.

This

patient was also being treated with oral iron for chronic
anemia (Rank et al. 1988).

Vibrio damsela and V.

alginolvticus cause wound infections.

Although common in

the marine environment, V. alainolyticus is a rare pathogen.
Vibrio damsela was first recognized as a fish pathogen.

Of

twenty-two isolates studied by the Centers for Disease
Control, Atlanta, Ga.

(CDC), seven were from fish, and ten

were recovered from wound infections in humans (Love et al.
1981; Morris et al. 1982; Farmer et al. 1985; Clarridge and
Daum 1985).
A ten year longitudinal study of Vibrio infections in a
Gulf Coast community was reported by Bonner in 1983.
Although this study spanned ten years, only 23 Vibrio
isolates, were recovered.
were V. vulnificus

Of the twenty-three isolates 12

(4 from wound infections, 5 from wound

infections with bacteremia, and 3 from bacteremic patients),
5 were V. parahaemolvticus. 4 were V. cholerae Non-01, and 2
were V. alainolyticus.

Most of these infections occurred

from April to October when the weather was the warmest
(Bonner et al., 1983).
The dermal lesions caused by V. vulnificus described by
Beckman et.al. were characterized by acute cellulitis, which
spread from the initial wound into adjacent tissue (Beckman
et al. 1981).

The superficial dermis becomes separated from

the underlying tissue by the formation of a non-inflammatory
subepidermal bullae or vesicle.

The dermis becomes necrotic

but shows no inflammation.

The vesicles contain many

organisms, especially at their base but, like the dermis, no
inflammation is seen.

The organisms are found extending

down into the subcutaneous tissues where extensive
cellulitis accompanied by inflammatory infiltration leads to
tissue damage and edema.
blood vessels,
necrosis.

Edema, by putting pressure on the

interrupts the flow of blood and enhances

Surgical intervention is often necessary to

restore blood flow and save adjacent healthy tissue from
further damage.

There is also a tendency for the organisms

to be found around the blood vessels (Beckman et al. 1981).
Vibrio vulnificus produces a number of virulence factors
that aid in establishing dermal infection: siderophores,
proteases, collagenases, phospholipase, lysophospholipase,
cytolysins, hemolysins, and extracellular toxins (Simpson et
al. 1983; Kothary and Kreger 1985; Smith and Merkel 1982;
Testa et al. 1984; Gray and Kreger 1985; Tison and Kelly
1984; Kreger and Lockwood 1981).
A second form of V. vulnificus infection is primary
septicemia.

This septicemia is characterized by general

malaise, chills, fever, vomiting, hypotension and, in some
cases, diarrhea (Blake et al. 1980).

Within forty-eight

hours following onset of a V. vulnificus infection cutaneous
lesions appear, most often on the lower extremities (Bonner
et al. 1983).

These lesions are similar to the lesions

observed in wound infections.

It has been suggested that
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these cutaneous lesions are caused by the hematogenous
spread of the organism (Blake et al. 1980; Bonner et al.
1983).

This is supported by the work of Johnston et al.

(1985) which shows that chronic liver disease, especially
cirrhosis, hematopoietic disorders, chronic renal disease,
alcoholism, the use of antacids or cimetidine (ie., TagametR
and probably others such as ZantacR) and the use of
immunosuppressive drugs are strongly associated with V.
vulnificus septicemia.

Exposure to sea water or injury

while handling raw shellfish does not show a positive
correlation with primary septicemia.

There is, however, a

strong positive correlation between consumption of raw
oysters and septicemia.

The point of entry for the

infectious agent in cases of primary septicemia seems to be
a break in the gastrointestinal tract, such as an ulcer,
followed by the consumption of contaminated raw seafood.
Poliak et al.

(1983) recovered V. vulnificus from the blood

and stool of an alcoholic patient with primary septicemia.
They also detected anti-V. vulnificus antibody in the serum
of this victim.

In the ten year survey of vibriosis in Gulf

Coast community, noted earlier, Bonner, et al.

(1983)

reported that only a small percentage of the patients with
severe diarrhea produced stool specimens from which Vibrio
species could be isolated.

MacConkey's agar was sufficient

to recover 2 of the 3 isolates from stool specimens,
although the recommended medium is TCBS agar.

Seventy-five percent of patients with primary
septicemia suffered from some form of liver disease such as:
hemochromatosis, cirrhosis or hepatoma.

Many of the

remaining patients had other serious diseases: alcoholism,
thalassemia, diabetes and leukemia or other malignancies
(Blake et al. 1980).

Increased serum iron levels in

victims, coupled with the fact that V. vulnificus produces
siderophores which acquire iron from host iron sequestering
proteins such as haptoglobin, hemoglobin, hematin,
hemoplexin,

lactoferrin, methemoglobin (Simpson and Oliver

1983; Andrus et al. 1983; Helms et al. 1984) has led to
investigations into the relationship of V. vulnificus
disease to serum iron levels.

Wright, et.al.(1981), found

that increasing the serum iron level in mice by parental
injection of iron compounds decreased the LDS0 from 106 cells
to 1.1 cells.

Elevated serum iron levels also impair some

host defense mechanisms

(Weinberg

1978), and V. vulnificus

appears to be more resistant to the bactericidal properties
of normal serum than are other Vibrio species (Carruthers et
al. 1981; Tamplin et al. 1983; Johnson et al. 1984; Ward et
al. 1986).
In many instances, the primary source of the infectious
agent can not be identified.

Tacket et al.(1984), reported

a wound infection in a patient exposed to water from a
brackish inland creek but, without exposure to seafood or
seawater.

Mertens et al.

(1979) described a fatal case of
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septicemia in which the victim with acute enteritis claimed
no recent exposure to the sea.

It is also possible for the

presenting symptoms to be different from those described
above for primary septicemia.

Kelly and McCormick (1981),

report a case of fatal septicemia in which the presenting
symptom was lower leg pain.

In each of the latter cases

there was a history of diarrhea preceding the onset of acute
symptoms.

Kelly also reports a case of pneumonia caused by

V. vulnificus in a drowning victim (Kelly and Avery 1980).
A case of acute endometritis caused by V. vulnificus
occurred in a patient who had no history of raw seafood
consumption, however, she admitted to having engaged in
sexual intercourse while "swimming" in the Gulf of Mexico
(Tison and Kelly 1984).
At present, the clinical pattern of disease production
has been described thoroughly.

Two major obstacles remain

in the clinical management of V. vulnificus infections.
First, education of the public so that these infections are
brought promptly to the attention of the medical community.
Second,

increasing the awareness of the primary care

physicians,
of

in endemic areas, to insure that the possibility

V. vulnificus is considered in the differential

diagnosis of septicemias and wound infections where a link
to the marine environment is known (FDA 1988).
The laboratory identification of V. vulnificus
infections is both time consuming and expensive.

Several

14
days are required for a definitive identification.

This

long period of time makes culture and follow-up bacteriology
impractical for both clinical diagnosis and environmental
screening.
Two current approaches for rapid identification of a
microorganism are DNA probes and antigen detection.
techniques are specific and sensitive.

Both

At the present time

two gene probes have been constructed to detect V.
vulnificus: one for the toxin gene and a second for the
chitinase gene.

The toxin gene shows the most promise as a

diagnostic probe (Wright et al., 1985; Wortman et al.,
1986).

Utilization of DNA probes in the clinical

microbiology laboratory requires skilled personnel and a
well equipped laboratory.

Some of the problems encountered

with the utilization of DNA probes can be eliminated by
using monoclonal antibody based antigen detection reagents.
Monoclonal antibody based assays such a enzyme
immunoassay (EIA), Latex or Co-agglutination can be
completed within one hour.

Equipment needed to perform

these assays is minimal and most laboratory technicians are
familiar with these techniques.
When designing prototype rapid identification reagents
several questions must be asked.

First, is there a "non-

pathogenic" or "avirulent" biotype of this organism in the
environment?

A practical procedure must differentiate non

pathogens from the pathogens.

Second,

is there a

characteristic that is exclusively associated with
virulence?

An "in vitro" correlate of virulence may be a

morphological, biochemical or antigenic difference between
the virulent and avirulent organisms.
must be answered.

A final question that

What is the minimal lethal dose of V.

vulnificus for humans?

The answer to this question may

never be known, but, it is possible to assess the virulence
of this organism based on animal models.
This dissertation will be divided into three chapters.
The first chapter will outline the characterization of the
Louisiana V. vulnificus isolates used in this study.

The

second chapter will deal with the production of vaccines to
produce high titered polyclonal antisera for use in an LPS
based serotyping scheme for V. vulnificus.

The third

chapter will cover the affinity purification of polyclonal
antisera and the development of
V. vulnificus serovars.

monoclonal antibodies for

Chapter I Characterization of Vibrio vulnificus
Isolates from Louisiana
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Abstract

Twenty-three different V. vulnificus strains isolated
in Louisiana were examined to determine if these strains
resembled phenotypically the ATCC type strain for this
species.

The human and environmental isolates were screened

for reactions on Kliger's Iron agar (KIA), Lysine Iron Agar
(LIA), and TCBS agar.

These same isolates were then

screened for hemolysin production, lethality for Balb/c mice
and clearance from the peripheral blood stream of the
rabbit.

The Louisiana isolates were hemolytic, lethal for

Balb/c mice and were all rapidly cleared from the blood
stream.

Opaque and translucent phenotypes of five V.

vulnificus were isolated.
phenotype change occurred.

Only the opaque to translucent
These phenotypic variants were

then screened for plasmid content.
were found to carry a plasmid.

None of these strains

This suggests that the

mechanism for opaque to translucent switching is genomic.
The V. vulnificus isolates were tested to determine the
bactericidal effect of apo-lactoferrin.

All of the V.

vulnificus isolates screened showed resistance to apolactoferrin.
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Introduction

Vibrio vulnificus. a recent addition to the genus
V i b r i o , has been recognized as a human pathogen for only a
decade, there are several questions relating to this
organism that remain to be answered.

First, does each

Louisiana V. vulnificus isolate resemble phenotypically the
ATCC type strain # 27562?

Second, are there differences

between human and environmental isolates?

Finally,

is

there a non-pathogenic or avirulent phenotype of V.
vulnificus?
Twenty-three Louisiana isolates were compared with the
ATCC type strain and isolate E4125 (Centers for Disease
Control, Atlanta, Ga.) by a minimum number of biochemical
tests to determine that each isolate was, in fact, V.
vulnificus.

In addition, each isolate was examined for

hemolysin production, mouse lethality and, clearance from
the peripheral blood stream of the rabbit.
These preliminary studies provided some insight into
the type of disease produced and confirmed that the
Louisiana isolates were pathogenic.

From this point the

research branched off in two different directions.

First

the production of a capsular or slime layer was examined.
Isolates were screened for capsule production (opaque
colonies) or lack of capsule production (translucent

18

colonies).

After opaque and translucent colony types had

been isolated, each phenotype was screened for plasmid
production.

Finally, the sensitivity of Vibrio vulnificus

isolates to the bactericidal action of apo-lactoferrin was
tested.

Materials and Methods

Bacterial Strains.

Twenty-three Louisiana V. vulnificus.

isolated from humans and the environment were provided by
the Louisiana Department of Health and Human Resources,
Division of Laboratories (Table 1).
#27562

Vibrio vulnificus ATCC

(American Type Culture Collection, Rockville, Md.)

and isolate E4125 (Dr. R.E. Weaver and Dr. D. G. Hollis of
the Centers for Disease Control, Atlanta, Ga.) were used as
the prototype strains (Table 2).
Culture Identification and Maintenance.

Bacterial cells

were grown at 37° C on alkaline peptone agar pH 8.0 (1%
peptone, 2% NaCl,

1.5% agar, 0.2% yeast extract).

isolate was stored on maintenance media

(8

Each

grams Bacto

Tryptone, 5 grams NaCl, 4 grams Nutrient Broth, 4 grams
agar, qs to 1 liter with dH 20) .

To insure consistency,

bacterial strains were maintained in a frozen state in 15%
glycerol tryptic soy broth as well as on maintenance media.
Each strain was inoculated on Kigler's Iron agar (KIA),
Lysine Iron Agar (LIA)

(supplemented to 2% NaCl) and

Thiosulfate-Citrate-Bile-Salt agar (TCBS) to insure that
pure cultures were maintained (Table 3).
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TABLE 2.
Louisiana Vibrio vulnificus isolates, patient
information, and strain designations.
All isolates were
received from the Louisiana Department of Health and Human
Services Division of Laboratories.
Isolate

Sp. Dis Outcome

Vv 846
VvlOOO
VvlOOl

c
s

Seafood Contact Age Sex

Lived
Lived
Died

Raw Oysters*
Unknown
Raw Oyster,
Crayfish

7

B

WI
D
PS

69
41

M
M
M

W1002

B

PS

Lived

Unknown

55

M

Vvl003
Vvl004
Vvl005
VV1006
VV1007

B
S
B
B
B

WI
D
PS
PS
PS

Lived
Lived
Died
Lived
Died

Crab Puncture
Raw Oysters
Raw Oysters
Raw Oysters
Raw Oysters,
Crab

64
53
73
52
69

M
M

Vvl008

S

D

Lived

Raw Oysters

28

M

VV1009

B

PS

Died

58

M

VvlOlO

B

PS

Died

Raw Oysters,
Crab
Unknown

83

M

Vvl012

P

PS

Died

Raw Oysters

60

M

Vvl013
VV1014
Vvl015
Vvl355
VV1365

B

7
7
7
Lived
Lived

7
7
7
7

7
7
7
67
70

M
7

B
W

PS
7
WI
WI
WI

M
M

Vvl456

W

WI

Lived

7

75

M

VV2098

7

7

7

7

7

7

7
7

B= Blood
S= Stool
P=Peritoneal fluid
PS= Primary septicemia
WI= Wound Infection
? = Not Available

7

C=Cornea
D= Diarrhea
Sp=Specimen type
Dis= Disease

M
F
F

7

Hist.
None
CA,Ulcer
Cirrhosis
Ulcer
Ren.Dis.
Cirrhosis
Diabetic
Kid. Inf.
Ulcer
Leukemia
Alcoholic
Ulcer
Ren. Dis.
Diabetic
Chronic
Indigest
Cancer,
Ren. Dis.
Cirrhosis
Cancer,
Ulcer
Ren. Dis.
HeartDis
7
7

7
Alcoholic
Cancer
HeartDis
Chronic
Pulm.Dis
7
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Freezing Bacterial Cultures.

Bacteria were harvested from

the surface of an alkaline peptone slant in 3.0 ml of
cryostorage solution (Tryptic Soy Broth, 5% glycerol).

One-

half ml of bacterial suspension was placed in cryotube
(Nalge, A Division of Sybron Corporation, Rochester, N.Y.).
Tubes were immediately stored at -70° C.

The frozen stock

cultures of V. vulnificus isolates were collected between
1977 and 1982.

These organisms have been frozen and thawed

as well as being held on maintenance media for several years
prior to being frozen during the summer of 1988, and may
differ from the original isolate recovered from the clinical
or environmental specimen.
Hemolysis Assays.

The ability of V. vulnificus to lyse both

rabbit and mouse erythrocytes was determined on blood agar
plates.

Blood agar was prepared by adding a 5% suspension

of donor erythrocytes to alkaline peptone agar, pH 7.2.

The

blood was obtained aseptically from either Balb/c mice or
New Zealand White rabbits.

Each plate was then divided into

quadrants, and each isolate tested was struck onto one
quadrant on each of three separate plates.

The results were

recorded as a-hemolytic if partial hemolysis was observed,
B-hemolytic if complete hemolysis was observed, and

r-

hemolytic if no hemolysis was seen (Table 4).
Mouse Lethality.

The lethality of V. vulnificus for mice

was determined by intraperitoneal injection (I.P.) of a
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standardized live vaccine.

Since a baseline lethal dose

value was not available, two pilot studies were done. In the
first study, for each of the five isolates tested, a single
mouse was injected I.P. with 5 x 109 live organisms. The
animals were then observed every two hours.
pilot study seven strains were tested.

In the second

This second

experiment used five mice for each strain tested.

Each

mouse was injected I.P. with 1 x 108 live V. vulnificus
cells.

At this point, enough preliminary data was available

to do a quantitative LD50.
Determination of LD50. The protocol for the determination of
an LD 50 for V. vulnificus, based on the method of Reed and
Muench (1938), was submitted to the animal care and use
committee.

The animal care and use committee rejected the

protocol, and no reason for this rejection was communicated
to the author.

Because the above cited protocol is the only

long standing, universally accepted method for determining
fifty per cent endpoints available and the fact that the
committee wasn't forthcoming with any specific complaints,
this experiment was abandoned.
Translucent and Qpaoue Strain Variation.

Each V. vulnificus

strain used in this study had been cultured continuously on
maintenance medium since 1982.

It was not unusual to see

various sizes of colonies in a pure culture.

All V.

vulnificus strains in the collection were subcultured on
alkaline peptone agar, using an oblique light source.
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Opaque and translucent colony types were separated where
possible.

Both translucent and opaque strains were isolated

from W 8 4 6 , W 1 0 0 5 , W 1 0 0 7 , Vvl008, and W 1 0 1 3 .
Capsular Phenotype Switching.

To determine if opaque to

translucent switching was bidirectional or unidirectional a
single colony of each opaque and each translucent phenotype
was inoculated into alkaline peptone broth.

These organisms

were grown at 37° C overnight and a 10 ul was transferred to
a second broth.

The organisms were serially passed from

tube to tube for five days, then plate counts were done.
Plasmid screening.

The translucent and opaque phenotypes of

Vvl005, Vvl007, Vvl0 0 8 , and Vvl013 were screened for
plasmids.

DNA preparations were separated by electro

phoresis on 0.7% agarose gels, stained with ethidium
bromide, and observed with 360 nm U.V. light (Birnboim and
Doly 1980).
Clearance of opaoue and translucent variants in rabbits.
New Zealand White rabbits were immunized with 109 live V.
vulnificus via intravenous injection in the marginal ear
vein.

Blood was drawn immediately from the central artery

of the opposite ear as a time zero bacterial plate count.
Dilutions of blood samples obtained at 10, 20, 30, 40, 50,
and 60 minutes post injection were plated on alkaline
peptone agar.
Lactoferrin Susceptibility.

The susceptibility of V.

vulnificus to the bactericidal action of human lactoferrin
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was determined by exposing V. vulnificus cells to apolactoferrin (iron free lactoferrin).

Five mg of human apo-

lactoferrin (Sigma chemical Co., ST. Louis, Mo.) was
dissolved in 2 ml acetate-EDTA buffer containing 0.2 M
NaH 2P04, 0.04 M EDTA,

0.2 M acetic acid, 0.2 M sodium

acetate, pH 4.0, and dialyzed against six changes of
acetate-EDTA buffer to remove residual iron, followed by
dialysis against two changes of double glass distilled water
to remove the acetate-EDTA buffer.

The apo-lactoferrin

solution was standardized to 2.5 mg per ml and stored at
-70° C.

Vibrio vulnificus cells were harvested in 2 ml of

0.067 M PBS from the surface of alkaline peptone agar
slants.

The cell suspension was added dropwise to 25 ml

alkaline peptone broth, in a side arm flask, until the
turbidity reached 36 Klett units (3.0 x 108 cells per ml).
The flask was incubated at 37° C with shaking until the
turbidity reached 75 Klett units.

Cells were sedimented at

2,800 x g, for 10 minutes and resuspended in 0.067 M PBS to
36 Klett units ( 3.0 x 108 cells per ml).
tube,

0.1

ml of cell suspension was added,

To a 13 x 100 mm
0.1

ml of apo-

lactoferrin, and 0.9 ml alkaline peptone broth pH 7.2.

The

negative control tube received the Vibrio suspension but,
did not receive apo-lactoferrin.

A time zero sample (0.10

ml) was removed and immediately diluted in 0.067 M PBS for
aerobic plate count.

The tubes were then incubated at 37° C

for four hours, at which time a second aliquot of the
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reaction mixture was removed, and plates counts were done
(Table

8

).

Results and Discussion
Twenty-three V. vulnificus isolates were examined to
determine if these strains phenotypically resembled the ATCC
type strain 27562 and CDC isolate E4125.

The disease caused

by the twenty human isolates was what was to be expected
from a review of the literature (Thorsteinsson et al. 1974;
Blake et al. 1979; Blake et al. 1980; Bonner et al. 1983).
The age and sex of the victims is known for fifteen of the
isolates, thirteen of the fifteen victims were male (8 6 %)
and had an average age of 61 years (Table 2).

There was a

history of consumption of raw seafood in thirteen of the
sixteen (81%) cases where information was available and all
of the patients had an underlying disease such as cirrhosis
or ulcers. In this small sample there was a 38% mortality
rate (6/16).
Each V. vulnificus isolate was inoculated onto
Kligler's Iron Agar (KIA), Lysine Iron Agar (LIA), and TCBS
agar to insure that pure cultures were maintained (Table 3).
Since these isolates had been exhaustively reidentified many
times in our laboratory, they were not subjected to
additional testing.
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TABLE 3. Biochemical characteristics used to screen Vibrio
vulnificus isolates.
Media adjusted to attain a 2% NaCl
concentration.
Reaction read at 24 h.
Isolate

TCBS
Sucrose

Vv 846H
VvlOOOH
W1001H
W1002H
W1003H
W1004H
W1005H
W1005T
W1005O
W1006H
W1007H
W1007T
W10070
W1008H
VV1008T
W10080
W1009H
VvlOlOH
W1012H
W1013H
W1013T
W10130
W1014H
VV1015H
W1355H
W1365H
W1456H
W2098H
WE4125
WATCC27562
W125E
W137E
W158E
VCVCE271

0
0
0
0

+
0
0
0
0
0
0
0
0
0
0
0
0
0
0

+
0

+
0
0
0
0
0
0
0

0
0
0
0

+

KIA

LIA

K/A°
K/A°
K/A°
K/A°
K/A°
K/A"
K/A°
K/A°
K/A”
A/A”
K/A”
K/A°
K/A”
K/A”
K/A”
K/A”
K/A”
K/A°
K/A”
K/A"
K/A”
K/A”
K/A'
K/A”
K/A°
K/A”
K/A”
K/A”
K/A”
K/A”
K/A°
K/A”
K/A”
K/A”

K/K°
K/K"
K/K°
K/K°
K/K°
K/K°
K/K°
K/K°
K/K”
K/K°
K/K°
K/K°
K/K”
K/K”
K/K°
K/K”
K/K°
K/K°
K/K”
K/K°
K/K°
K/K°
K/K”
K/K°
K/K°
K/K°
K/K°
K/K°
K/K°
K/K°
K/K°
K/K°
K/K°
K/A°

H= Human isolate
T= Translucent
E= Environmental isolate
Vv= V. vulnificus
Vc= V. cholerae (control)
K= Alkaline]
A= Acid
°= No Gas

Froz«

0= Opaque

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
0
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To determine whether a non-pathogenic or virulent V.
vulnificus strains existed, we chose to screen our isolates
for hemolysin production and pathogenicity in mice.

One of

the classic characteristics of a virulent pathogen is the
ability to produce hemolysins.

All of the Louisiana V.

vulnificus isolates were found to hemolyze mouse blood
within forty-eight hours, and ten of thirteen (77%) were
hemolytic on rabbit blood agar (Table 4).

These results

agree with the reports in the literature (Johnson and Calia
1981).
Each of the twenty human V. vulnificus isolates and
each of the environmental isolates was tested for
pathogenicity using Balb/c mice.

In the first experiment, a

single mouse was injected intraperitoneally with 5 x 109 V.
vulnificus cells.

Thirteen human isolates and 7

environmental V. vulnificus isolates were tested (Table 5).
Two of the human isolates (W1008, W 1 0 0 9 )

were non-lethal

for Balb/c mice at 5 x 109 cells, all the remaining strains
18/20

(90%) tested were lethal within twenty-four hours.

a second experiment,

In

1 x 10® V. vulnificus cells were

injected intraperitoneally into Balb/c mice.

This lower

cell inoculum was chosen so that an infection more closely
resembling a naturally occurring infection would result.
Seven V. vulnificus human isolates were tested at 1 x 108
cells per mouse.

Two strains were found to be more rapidly
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TABLE 4. Hemolytic patterns for representative Vibrio
vulnificus human isolates observed on rabbit blood agar
(rRBC) and mouse blood agar (mRBC) plates following 24 and
48 h of incubation.
24 hrs.
Isolate
VvlOOOH
W1002H
W1003H
W1004H
W1005H
W1006H
VV1007H
VV1008H
W1009H
W1010H
W1012H
W1013H
W1015H

mRBC

r

48hrs •
rRBC

B

B
Bw
B
Bw
B

r

r

B
B

Bw
Bw

r
r

r
r
r
r

B
B

r

B
B
B

B= Beta hemolytic
r= Gamma hemolytic
w= weakly hemolytic
H= Human isolate

Bw

mRBC
B
B
fi
B
B
B
B
B
B
B
B
B
B

rRBC
Bw
Bw
B
Bw
B

r
Bw
Bw

r
r
Bw
Bw
B
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lethal (W1 0 0 2 , Vvl012) , killing the mice within four hours,
and two strains were found to be less lethal (Vvl008,
W E 4 1 2 5 ) , allowing the mice to survive beyond twenty-four
hours, with the remaining three strains falling between
these two extremes (Table

6

).

The next logical experiment

would be to take a highly virulent strain (Vvl002) and a
less virulent strain (Vvl008) and determine the LD50,
however, as noted previously, we were not allowed to conduct
that experiment.

Using the qualitative information that was

available from the lethality studies we decided to
investigate the contribution of cell surface components to
virulence.
This direction was taken because Bowdre et al.

(1981)

have shown that V. vulnificus cells implanted subcutaneously
within a diffusion chamber could survive several weeks in
vivo without producing a lesion.

The membrane (0.2 urn) on

this chamber prevented direct contact of the organism with
the host but, would allow for the free diffusion of
bacterial products.

Since presumably the V. vulnificus

toxin (M.W. 56Kd) would be able to diffuse into the
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TABLE 5. The virulence of selected environmental and human
V. vulnificus isolates for Balb/c mice injected with 5 x 109
cells by the intraperitoneal route.
Isolates

2h

4h

6h

8h

lOh

12h

24h

36h

VvlOOOH ................................ D
W 1 0 0 2 H .... D°
W 1 0 0 3 H ................................ D
VV1004H ................................ D
VV1005H
D
W 1 0 0 6 H ........................... D
W 1 0 0 7 H .... D
W 1 0 0 8 H ........................................... Sb
W 1 0 0 9 H ........................................... S
VvlOlOH ................................ D
VV1012H
D
VV1013H ................................ D
W 1 0 1 5 H .... D
W118E
................................ D
W125E
................................ D
VV133E
................................ D
W137E
........................... D
W140E
................................ D
W142E
................................ D
W149E
................................ D
Control ............................................ S
aD= Deceased
bS= Survived

48h
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TABLE 6 . Time course mortality study of seven
vulnificus isolates.
Five mice were used for
tested.
Mice were injected intraperitoneally
live cells at time zero (00.) and observed at
intervals for eighteen hours.
Time

Mice Remaining Alive

Hours W 1 0 0 2
.00

human V.
each strain
with 1 x 108
30 minute

5

W1005
5

Vvl007
5

W1008
5

VV1012

Vvl015 VvE4125
5

5

5

.50
3

1.00

1.50

2

2.00

0

2.50
3:00
3.50
4.00
4.50
5.00
5.50

4
2
1

4

6.00

2

4

6.50
7.00
7.50
8.00

18.0

0

4
3

1

0

0

1

4

0

0

5
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interstitial fluid, one would expect at least some local
edema.

The toxin produced by V*. vulnificus was first

described by Kreger and Lockwood (1981).

This toxin

wasisolated from culture filtrates and was found to be
cytotoxic, hemolytic,

lethal for mice, and to increase the

vascular permeability in guinea pig skin (Gray and Kreger
1985).

Due to the necessity for direct contact between the

bacterium and the host for disease production, cell surface
characteristics were involved in V. vulnificus disease.
The search for a cell surface component that was
associated with virulence should to be directed at molecules
exposed on the cells surface such as outer membrane proteins
(OMP's), lipopolysaccharide (LPS), and capsule.
The lipopolysaccharide antigen profile of V. cholerae
has been very useful in both diagnostic and epidemiological
studies.

The previous success with LPS serotyping of V.

cholerae made the LPS an obvious first choice for a
virulence marker.

The development of an LPS serotyping

scheme for V. vulnificus will be covered in chapters two and
th r e e .
Many strains of JL vulnificus produce a layer of
polysaccharide slime or capsular material.

Viewing colonies

grown on clear media with an oblique light source, it is
possible to distinguish both opaque and translucent colony
types (Amako et al. 1984; Yoshida et al. 1985).

Yoshida et
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al. have shown that the LD50 for mice and the ability to
resist the bactericidal action of serum varies depending
upon the opacity of the strain.

The opaque strains show an

decreased LD S0 and an increased resistance to the
bactericidal activity of serum as compared to the
translucent strains.

Because of the antiphagocytic

properties of bacterial capsules in general and the reports
that V^. vulnificus is less susceptible to phagocytosis than
other vibrio pathogens, this capsular material seems to be
important (Kreger et al. 1981; Tamplin et al. 1983; Tamplin
et al. 1985).

It has also been reported that capsular

materials may be useful as vaccines and that passively
transferred anticapsular antibody

may raise the LD 50 by up

to 40-fold (Cryz et al. 1984; Cryz et al. 1985).
Opaque (encapsulated) and translucent (non
encapsulated) phenotypes of five Louisiana V. vulnificus
have been isolated (Figure 1).

Starting with "pure"

cultures of opaque cells and passing the culture from broth
to broth for five days a mixed culture of both opaque and
translucent cells was recovered.

If the starting culture

was a translucent phenotype, only translucent cells were
recovered.

The opaque to translucent phenotype switch

occurred rapidly, however, the translucent to opaque switch
was not observed (Table 7).

The actual rate of this

switching is difficult to determine because in addition to
the translucent and opaque phenotypes there are a large
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number of sectored colonies containing both phenotypes (Fig.
1).

These colonies show a sector of translucent and a

sector of opaque growth.

In the sectored colonies, the

opaque variant accounts for the majority of the colony with
< 25% being translucent.

Some opaque colonies have more

than one translucent sector.

There have been no translucent
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TABLE 7.

Frequency of switching from opaque to translucent

and translucent to opaque phenotypes of Vibrio vulnificus.
Pure culture of opaque or translucent that had been passed
daily for five days from broth to broth.
values

Results are mean

of three experiments.

Colony Types
Original Strain

Opaque(%)

Translucent(%)

VV1005-0

2 X 10 7 (17.4)

9.5 X 107 (82.6)

W1005-T

None

2.5 x 107 (100)

W1008-0

4.5 x 107 (56.2)

3.5 X 107 (43.8)

W1008-T

None

4.0 x 10 7 (100)

W1013-0

5.5 x 107 (64.7)

3.0 x 10 7 (35.3)

VV1013-T

None

1.0

x

108

(1 0 0 )
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Figure 1. Translucent and opaque phenotypes of V.
vulnificus strain Vvl005H on alkaline peptone agar pH 8.0.
Note the numerous sectored opaque colonies.
No sectoring is
observed with the translucent phenotype.
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colonies that have opaque sectors observed.

Due to

sectoring of the colonies an accurate conversion can not be
established by simple plate count.
microscope studies, Yoshida et al.

Using electron
(1985) estimated the

opaque to translucent switching rate at «

2

x

10

'4, they

also estimated a translucent to opaque switching rate at <
1.8

x

1 0 '4.

Some strains, such as ATCC 27562, appear to be light
variants.

This may be a laboratory artifact.

In the

selection of colonies to be placed in maintenance medium, a
single translucent variant may have been selected for
transfer which would have eliminated the opaque variants.
These cultures may then be carried as translucent variants.
Opaque and translucent phenotypes were screened for
plasmids because loss of a plasmid would conveniently
explain a unidirectional phenotype switch.
found in any of the organisms tested.

No plasmids were

Studies by Davidson

and Oliver (1986) found plasmids in only 12% of V.
vulnificus isolates tested, and these plasmids were found to
be a various molecular weights, none of the human isolates
contained a plasmid.
The final study undertaken has been the testing of V.
vulnificus sensitivity to lactoferrin.

Lactoferrin is

produced in neutrophils and in the acinar epithelial cells
that line mucous membranes.

Lactoferrin is found in mucous

secretions, and milk and has been shown to have a
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bacteriostatic effect (Bullen et al. 1978; Weinberg 1978).
This bacteriostatic effect can be abolished by adding enough
iron to the system to saturate lactoferrin's iron binding
capacity.

It was therefore thought that lactoferrin

functioned to chelate iron thereby making it unavailable for
the bacteria.

The addition of iron compounds above levels

that can be bound by serum proteins is also detrimental to
neutrophil function and lowers the antibacterial effect of
human plasma (Ward et al. 1986).
A bactericidal activity for human lactoferrin was
first demonstrated by Arnold et al. in 1977.

Lactoferrin

has been found to be bactericidal for a wide variety of
microorganisms (Arnold et al. 1980; Mickelsen et al. 1982;
Bortner et al. 1986).

Some of these organisms have been

found to able to obtain iron from lactoferrin (Mickelsen et
al. 1982).
The

sensitivity of Vs. vulnificus to lactoferrin was

tested by exposing the organism to Apo-lactoferrin (iron
free) and doing plate counts over a four hour period.

The

results indicate that the nine V^. vulnificus strains tested
were insensitive to the bactericidal activity of
lactoferrin, which would make these strains less susceptible
to polymorphonuclear leucocytes (PMN) and secretory immunity
(Table

8

).

If lactoferrin caused no change in bacterial

growth, both test and control cultures would be expected to
grow at the same rate, one would expect a growth.index of
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TABLE 8 . The sensitivity of Vibrio vulnificus isolates to
the bactericidal effects of apo-lactoferrin.
Log phase V.
vulnificus cells « 10 5 cells per ml. Test tubes received 250
ug per ml apo-lactoferrin.
Control tube received broth
only.
All plate counts done in triplicate.

VvlOOO

T 0 2.4 X 1 0 6

1.7 X
1.5 X

107

3.4 X
4.9 X

107
108

3.9 X
1.9 X

104

1.9 X
3.7 X

104

105

0 4.1 X 1 0 3

5.0 X

103

X

103

3.0 X
4.7 X

105

107

1002

T_o 5.6 X
T 4 3.4 X

107

Vvl003

T„o 4.0 X

104

8.0

X

107

Tn
o 7.6 X
t4 1 . 6 X

104

T4

W A T C C 27562

1.3 X
1.7 X

105

106

0 1.5 X
t 4 3.0 X

103

2.5 X

103

105

1.0

X

105

T.o 2.5 X
t4 1 . 0 X

103

2.0

105

2.0

X
X

103

103

1.5 X
3.6 X

103

7.8 X
5.3 X

107

V. cholerae
(1403)

T0 2 . 1 X
t 4 4.7 X

V. cholerae

T.o 9.5 X
t 4 9.7 X

106

107
108

aG.I.= % increase in cell number w/o LF
% increase in cell number w/ LF

1.9

106

T„0 1.3 X
T4 3.0 X

105

.85

104

•

106

1.2

104

o
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W
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.01

105
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.20
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•
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1.09

106

108

.63
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1.0 over the four hour test period.

A bactericidal effect

should have caused a negative growth index.

Of nine strains

tested three showed some inhibition, and six strains showed
no inhibition.

Both W 1 0 0 5 - T and W 1 0 0 8 - T showed less

growth than did their opaque counterparts (Table

8

).

The

bactericidal effect of lactoferrin can usually reduce the
numbers of organisms by several thousand fold. It therefore
seems unlikely that the small effect seen here is due to
this bactericidal effect.
The major questions to be addressed, with regards to
V. vulnificus are:
1. Are there LPS serotypes?
2. If there are LPS serotypes can they be used as
virulence markers,

i.e. in vitro correlates of

virulence?
3. Is there a different unique capsular polysaccharide
or is the difference between opaque and
translucent colonies simply a smooth and rough LPS
phenotype?
4. Does this proposed capsular material mask or hide
the LPS epitopes from the immune system?
5. Can a unique capsular polysaccharide be isolated and
used to serotype V. vulnificus?
Chapters two and three of the dissertation address the first
four questions.

Chapter II Production of Vibrio vulnificus SerovarSpecific Polyclonal Antisera
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Abstract
Immunization of rabbits with V. vulnificus produces a
low LPS or O antigen antibody titer as compared with titers
seen when other members of the genus V i brio, such as V.
cholerae. are used as an immunogen.

Vaccines were produced

using heat killed cells,

formalinized cells, and acetone

dried cell homogenates.

These preparations did not cause a

significant increase in the antibody titer.

Since the

response to whole cell vaccine was uniformly poor, the use
of polysaccharide-protein carrier conjugates was tested as a
way to increase the antibody titer.

LPS was extracted from

V. vulnificus and purified by both enzyme treatment and
differential centrifugation.

The poly-saccharide was then

removed from the LPS by alkaline hydrolysis and differential
centrifugation to pellet the lipid moiety.

Two methods of

conjugation were used. The first employed cyanogen bromide
as the linking agent, the second used benzoquinone as the
linking agent.

These PS-carrier conjugates did not enhance

the production of anti-V. vulnificus antibody.
These results demonstrate that V. vulnificus LPS is
less iitimunogenic than V. cholerae LPS.
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Introduction
The lipopolysaccharide associated O-antigen expressed
by Vibrio cholerae has proved to be an invaluable tool in
ecologic and epidemiologic studies. The O-antigen typing of
V. cholerae into the 01 and the non-01 groups also provides
a basis for the distinction between classical Asiatic
cholera caused by V. cholerae serovars Inaba and Ogawa (Ogroup

1

) and the usually less severe gastroenteritis caused

by the non- 0

1

's.

Considering the success of O-serotyping as applied to
V. cholerae it was practical to extend this approach to
other Vibrio species.

The first attempt to develop an 0-

serological typing scheme for V. vulnificus was reported by
Shimada and Sakazaki (1984).

In this scheme, heat killed

organisms were used to produce polyclonal antisera in
rabbits.

In the test system, whole cells that had been

heated to 100° C for two hours and washed twice were mixed
with antisera in tubes.

Cross-reactivity between many of

the strains tested could be removed by absorption of the
antisera with a "rough" strain.

Seven O-serological

varieties (serovars) were identified among 70 V. vulnificus
isolates examined by Shimada and Sakazaki

(1984).

Shimada also reported that many of the organisms they
examined were inagglutinable in the living state.

This

observation lead them to conclude that a heat-labile antigen
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was present that masked the O-antigens.
The typing scheme proposed by Shimada and Sakazaki is
based upon whole-cell vaccine and polyclonal antisera.
Although these techniques provide much valuable information,
a more precise typing scheme based on chemically defined
antigens is desirable.

A serological typing scheme based on

specific LPS antigens would eliminate non-specific results
and might provide for more accurate studies of serological
variation.
Two different problems have plagued us during the
course of these studies.

The first was our inability to

raise high titered antisera to V. vulnificus LPS.

The

second recurring problem was the cross reactivity observed
between V. vulnificus isolates.
Different approaches were investigated to prepare
immunogens for the immunization of rabbits.

Heat killed,

formalin killed, and acetone dried whole cell vaccines were
used.

Polysaccharide-carrier conjugates were prepared using

the cyanogen bromide procedure described by Adams and
Siebeling (1984), and using the benzoquinone procedure
described by Brandt et al.

(1975).

None of these techniques

produced a significant increase in the anti-LPS titer.

Materials and Methods
Whole Cell Vaccines.

Whole cell vaccines were produced by

growing V. vulnificus isolates on alkaline peptone agar (1%
peptone, 2% NaCl, 0.2% yeast extract, 1.5% agar, pH 7.3).
The cells were harvested with 0.15 M saline with 0.3%
formaldehyde (formalinized cells) or in 0.15 M saline.
Formalin killed vaccine cells, harvested with formaldehydesaline,

incubated at 4°-8° C for 48 hours and then

subcultured to insure that no viable organisms remained.
Heat-killed whole cell vaccines were prepared by incubation
of cells, harvested in saline, in a boiling water bath for
hour.

1

The heat-killed whole-cell vaccines were cooled and

subcultured to thioglycolate broth to insure that no viable
cells remained.

The formalin-killed and heat-killed whole

cell vaccines were standardized to
(380 Klett units at 520 N M ) .
immunized intravenously with

1

x

1 0 10

organisms per ml

New Zealand white rabbits were
1

ml of the standardized

vaccine every other day for three weeks.
Acetone Dried Cell Vaccine.

Selected V. vulnificus strains

were harvested in saline, washed once with saline, and
resuspended in

10

ml of acetone and stored at room

temperature overnight.

The cells were pelleted and allowed

to dry completely (2-3 days).

The desiccated cell mass was

ground into a fine powder with mortar and pestle.

The

acetone-dried cell powder was suspended in 0.067 M PBS
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were immunized intravenously over a three week period.

A

total of 8.5 ml of vaccine was administered over the
immunization period.
LPS Preparation.

Lipopolysaccharide (LPS) used in this

study was extracted from V. vulnificus isolates using the
hot phenol-water technique of Westphal and Jann (1965).
LPS detoxification.

The LPS consists of both a lipid and a

polysaccharide moiety.

To produce the protein carrier

conjugates, only the polysaccharide (PS) portion was needed.
The lipids were removed by alkaline hydrolysis.

Five

milligrams of LPS was suspended in 5 ml of distilled water,
0.1 ml of 1.0 N NaOH was added, and the mixture was
incubated at 37° C for 5 hrs.

Following incubation the

hydrolysate was dialyzed against 0.067 M PBS to neutralize
the NaOH.

The lipid was pelleted by centrifugation at

100,000 x g for 3 h.

The supernate was quantitated for

carbohydrate and adjusted to

1

mg carbohydrate per ml.

Preparation of Polvsaccharide-Carrier Conjugates.

Two

methods were used to conjugate PS to bovine gamma globulin
(BGG).

The first method employed CNBr to activate the PS

and the second used Benzoquinone.
CnBr Conjugation.

The CNBr coupled reagent was prepared

using the procedure of Adams and Siebeling (1984).
Polysaccharide was activated by dissolving 10 mg PS in 2 ml
0.15 M H 5BO 3- O .5 M NaCl pH

8

.6 .

To this solution 7 mg CNBr

was added and the mixture was stirred at room temperature at
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an alkaline pH for 15 minutes.

Ten ml of a 1% solution of

BGG (in borate-saline buffer) was added and the mixture was
stirred overnight at 4° C.

The PS-CNBr-BGG conjugate was

dialyzed against saline for 24 hours and the volume was
reduced to 5 ml using aquacide (Calbiochem, San Diego, Ca.).
Benzocruinone conjugation.

A PS-benzoquinone moiety was

prepared by utilizing a modification of the coupling
technique described by Brandt et al.

(1975).

Ten milligrams

of detoxified LPS (PS only) was dissolved in 5 ml of 0.067 M
PBS pH 7.3.

With constant stirring,

6

mg

of freshly

sublimed benzoquinone was added (0.2 ml of a 30 mg per ml
stock solution in absolute ethanol).

The mixture was

incubated at 4° C for 1 hour in the dark with constant
gentle stirring.

The benzoquinone activated PS was

precipitated by the addition of 20 ml of cold (-20° C)
absolute ethanol.

Ten milliliters of a 0.1% BGG solution (1

mg per ml in PBS) was added to the activated PS.

This

mixture was stirred gently, in the dark, at 4° C for
eighteen hours.

The PS-Benzoquinone-BGG conjugate was

dialyzed against PBS and the volume was reduced to 5 ml
using aquacide (Calbiochem, San Diego, Ca.).
Rabbits were immunized subcutaneously with 2.5 ml of
the PS-BGG conjugates emulsified in an equal volume of
Freund's complete adjuvant.

Twenty-one days later the

rabbits were boosted with 2.5 ml of conjugate emulsified
with Freund's incomplete antigen.
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O-Antiaen Tube Agglutination.

Live V. vulnificus cells

harvested from the surface of alkaline peptone slants in
0.15 M NaCl were washed two times and standardized to 1 x
109 cells per ml.

Serial two-fold dilutions of immune sera

were made in 0.5 ml volumes in saline.

Prebleed sera and

normal rabbit sera were used as control sera.

To each tube,

0.5 ml of standardized bacterial suspension was added.

The

contents of each tube was vortexed to insure complete
mixing,

incubated at 40° C for two hours and examined for

evidence of discernable agglutination.

The tubes were

reincubated at 4° C for 24 h and examined again for
agglutination.
Passive Hemagglutination.

Blood drawn from New Zealand

white rabbits was suspended in an equal volume with
Alsever's citrate-saline solution and held at least three
days at 4° C before use.

The RBCs were washed three times

in 0.15 M saline and resuspended in saline to 5% (v/v).

To

5 ml of a 5% RBC suspension, 5 ml of detoxified LPS solution
(50 ug per ml in 0.067 M PBS) was added.

The LPS-RBC

mixture was incubated for 2 h at 37° C with periodic mixing.
Sensitized RBC's were sedimented and washed one time in PBS.
Serial two-fold dilutions of heat inactivated test sera were
made in 0.5 ml volumes.

Heat-inactivated prebleed sera and

normal rabbit (obtained from RBC donors) sera were used as
the negative controls.

To each serum dilution, 0.5 ml of a

0.5% suspension of sensitized RBCs were added, and each tube
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was vortexed gently.

The tubes were incubated at 37° C for

ninety minutes and examined for agglutination.
were reincubated at 4° C
agglutination.

The tubes

for 24 h and read again for

Results and Discussion
Three different whole cell vaccines were used to
immunize rabbits in attempts to produce high titered anti-V
vulnificus polyclonal sera.

Rabbits immunized with

formalinized, heat-killed or acetone dried cells all
produced uniformly low anti-LPS titers in rabbits (Table 1)
The titers were ten-fold lower than PHA titers to V.
cholerae PS-sensitized rRBCs (Adams and Siebeling 1984).
The two possible reasons for the presence of low antiLPS titer are;

1) The polysaccharide is a poor immunogen.

2) The LPS epitopes may be covered by a capsular material,
effectively hiding these antigens from the immune system.
To differentiate between these two possibilities PScarrier conjugates were produced to eliminate the possible
interference caused by non-immunogenic capsule present on
the surface of the whole cell vaccines.

Two different

procedures were employed to couple PS to protein carrier;
the CnBr procedure used by Adams and Siebeling (1984) and
the benzoquinone procedure used by Brandt et al.(1975).
Rabbits immunized with these PS-carrier conjugates produced
low titers for V. vulnificus LPS (Table 1).

These results

suggest that the LPS of V. vulnificus is significantly less
immunogenic than LPS prepared from V. cholerae (Adams and
Siebeling 1984).

There are numerous reports of LPS acting
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TABLE 1. O-tube agglutination and PHA titers produced in
rabbits immunized with whole cells vaccines and PS-protein
carrier conjugates prepared from V. vulnificus 1005.

Agglutination Titers
Antigen

Technique

Titer

Formalinized cells (I.V.)

"0" Agg.a

160

Acetone dried cells (I.V.)

"0" Agg.

320

Heat killed cells (I.V.)

PHAb

PS-BGG conjugated with CnBr

PHA

256

PS-BGG conjugated with Benzoquinone

PHA

128

a= 0-Tube agglutination
b= Passive Hemagglutination
c= reciprocal of the greatest dilution of sera which
exhibits a discernable reaction.

8
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as an adjuvant and also acting as a suppressor of the In
dependent primary immune response (Persson, 1977; Sjoberg,
et al. 1972).

LPS has been reported to be able to activate

macrophages while at the same time it may inhibit Tlymphocyte transformation (Nelson 1973).

It is possible,

however, that the V. vulnificus LPS is a poor immunogen due
to it's chemical structure.

It is possible that non-

immunogenic capsular carbohydrate was co-purified with LPS,
diluting the immunogenicity of the LPS.
In summary, conventional whole vaccines or PS-protein
carrier conjugates do not provoke an acceptable level of
anti-LPS activity in the rabbit.

When low titer antiserum

is used in slide agglutination tests to serotype unknown V.
vulnificus isolates, undiluted serum may have to be used,
which may decrease specificity.

Chapter III Serotyping of Vibrio vulnificus Using
Lipopolysaccharide Specific Monoclonal Antibodies
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Abstract
A serotyping scheme for V. vulnificus based on
monoclonal antibodies specific for lipopolysaccharide (LPS)
antigens is proposed.

Previous typing schemes for V.

vulnificus have used heat-killed whole cell vaccines to
produce polyclonal antisera.

Polyclonal antisera produced

in this way cross-reacts with most heterologous strains.
Affinity purification of polyclonal antisera, using LPS
affinity columns, resolved some of these cross-reactions,
however, affinity-purified polyclonal antisera still showed
cross-reactions that were non-reciprocal.

On the basis of

the initial results with the affinity-purified polyclonal
antisera, strains were selected for the production of
monoclonal antibodies.

Balb/c mice were immunized with

formalinized whole cells.

Spleenocytes were collected from

immunized mice and fused with SP2/0-Ag 14 myeloma cells.
Hybridomas were screened using both lipopolysaccharide and
whole cell ELISAs to select clones secreting LPS specific
antibodies.

This approach was expanded to include Vibrio

damsela and Vibrio hollisae.
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introduction
Infections caused by V. vulnificus have been reported
in most parts of the world (Matsuo et al. 1978; Mertens et
al. 1979; Blake et al. 1979; Blake et al. 1980; Ghosh and
Bowen 1980).

Environmental surveys of V. vulnificus in the

United States show that V. vulnificus is found in virtually
all coastal areas during the warmer months of the year
(Matsuo et al. 1978; Blake et al. 1980; Ghosh and Bowen
1980; Kelly 1982;
Because of the

Oliver et al. 1982; Oliver et al. 1983).

widespread distribution of V. vulnificus and

its virulence for certain patient groups, rapid detection of
this organism is becoming increasingly important.
A species specific flagellar (H-antigen) antigen has
been identified and used in the rapid identification of V.
vulnificus

(Tassin et al. 1983; Simonson and Siebeling 1986;

Simonson and Siebeling 1988).

Shimada and Sakazaki (1984)

described a serotyping scheme based on direct agglutination,
of whole heat killed V. vulnificus cells with polyclonal
antisera raised in rabbits.

Because heat destroys the H-

antigens, the agglutination reactions observed were assumed
to represent reactions between cell wall associated Oantigen and antiserum.

The surface of the bacterial cell

presents various potential antigens to the rabbit's immune
system, therefore, antibodies directed against outer
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material are produced.

The inability to raise high titered

anti-LPS activity have made the use of polyclonal antisera
inefficient.

To date, a serotyping scheme based on

detection of lipopolysaccharide (LPS) antigens has not been
established for V. vulnificus.
Vibrio vulnificus has a capsule that covers the outer
membrane (Amako et al. 1984; Yoshida et al. 1985).

Because

the capsule may interfere with serological tests designed to
detect LPS determinants, both opaque (encapsulated) and
translucent (non-encapsulated) variants of V. vulnificus
were tested to determine the effect that this capsule would
have on LPS ELISAs done with LPS specific monoclonal
antibodies.
We propose a serotyping scheme based on purified LPS,
extracted from V. vulnificus.

Six hybridomas have been

established that produce LPS-specific antibody and react
with whole cells of six O-serovars by ELISA.

In addition to

V. vulnificus, monoclonal antibodies were also produced
against LPS extracted from V. damsela and V. hollisae.
These last two organisms were included because they are also
pathogenic for humans and cause infections that may resemble
V. vulnificus infection.

V. carchariae was used as a non

human pathogen Vibrio control.

No reports of human

infection with this organism exist.

Materials and Methods
Bacterial Strains Studied.

The following isolates were used

in this study: V. vulnificus strains: ATCC 27526, Louisiana
Department of Health and Human Resources (DHHR) strains
numbered: 846, 1000, 1001, 1002, 1003, 1004, 1005, 1006,
1007, 1008, 1009 1010, 1012, 1013, 1014, and 1015, CDC
strain E4125, V. hollisae ATCC 33564, V. damsela ATCC 35083,
V. carchariae ATCC 35084.

The variants Vvl005 opaque (0)

and Vvl005 translucent (T) were derived from DHHR strain
1005.
Production of Polyclonal Antisera.

Outbred New Zealand

white rabbits were immunized with formalinized whole cell
vaccines.

V. vulnificus cells were cultured on alkaline

peptone agar (1% peptone, 1.5% agar, 2% NaCl, 0.2% Yeast
Extract, Difco Laboratories, Detroit Michigan) at 37° C for
twenty-four hours.

Cells were harvested in 0.15 M NaCl

(saline) supplemented with .5% formaldehyde and held at 4° C
for forty-eight hours.

Each vaccine was inoculated into

thioglycolate broth (Difco Laboratories, Detroit, Michigan),
incubated at 37° C for twenty-four hours to insure that
cells were killed.

Vaccines which showed no growth in

thioglycolate broth were sedimented and resuspended in 0.067
M PBS to a concentration of 10 10 cells per ml.
immunized

with

1.0

Rabbits were

ml of standardized vaccine every two

days for a period of three weeks.

On day twenty-five, blood

was collected, serum was harvested and stored at -20° C
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until used.
LPS Extraction.

LPS was extracted from 1 to 5 grams of

acetone dried whole Vibrio cells.

The Vibrio cells were

grown on alkaline peptone agar at 30° C for 48 h and
harvested in 0.15 M NaCl. The cells were washed twice in
0.15 M NaCl, resuspended in acetone and held at room
temperature overnight.

The cells were washed twice with

acetone and dried at room temperature.

The dried cells were

ground to a fine powder with a mortar and pestle.
was extracted using the phenol-water
of Westphal and Jann (1965).

The LPS

extraction procedure

The LPS (1 mg per ml) was

detoxified by treatment with 0.25 N NaOH at 37° C for 4 h,
followed by 1 h at 56° C.

The detoxified material was

neutralized by dialysis against 0.067 M PBS at 4° C
overnight.

For use in ELISA, the LPS solution which

contained both lipid and polysaccharide (PS) was resuspended
to 50 ug per ml (LPS) in 0.067 M PBS, pH 7.3 and stored at 20° C.

A PS preparation was obtained by centrifugation of

the detoxified material at
lipid.

100,000

x g to sediment the

The supernatant, which contained the PS, was

lyophilized.
LPS Affinity Columh Preparation.

The purified PS was

coupled to an amino-hexyl sepharose matrix by a benzoquinone
bridge by the method of Girard and Goichot (1981).

The

column was equilibrated with 0.067 M PBS, pH 7.3 starting
buffer until a consistent O.D. was established at 280 nm.
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One ml of the whole anti-V. vulnificus serum was applied
directly to the top of the column and allowed to enter the
bed.

The serum was retained in the matrix for one hour at

room temperature to permit anti-LPS antibody absorption to
the LPS-matrix.

Unbound proteins were eluted with starting

buffer until the absorption at 280 nm had returned to
baseline.

The bound anti-LPS fraction was eluted with a 0.2

M glycine buffer pH 2.8.

The column was re-equilibrated

with starting buffer to pH 7.3.

The eluted anti-LPS

proteins were dialyzed against starting buffer to neutralize
the pH and concentrated to the original volume (1 m l ).

Each

column was used repeatedly over a period of several weeks,
then the matrix was retrieved and stored at 4° C in 0.067 M
PBS pH 7.3 with 0.2% NaN 3 added as a preservative.
Monoclonal Antibody Production.

Monoclonal antibody

secreting hybridomas were produced by fusing immune
spleenocytes collected from female Balb/c mice with non-Ig
secreting SP2/0-Agl4 cells (American Type Culture
Collection, Rockville, Md.).

The fusion protocol used was a

modification of the method used by Oi and Herzberg (1980).
Cells were fused in a ratio of four spleenocytes to one
myeloma cell in 50% polyethylene glycol M.W. 1500 in 75 mM
HEPES buffer (Boehringer Mannheim Biochemicals,
Indianapolis, Ind.).

Following fusion the cells were

suspended in RPMI medium supplemented with 2 mM glutamine
(Flow Laboratories, McLean, Va.), 0.2% NaC0 3 (Flow
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Laboratories, McLean, Va.), 1% Non-essential amino acids
(Flow Laboratories, McLean, Va.), 1% Hypoxanthine-Thymidine
(HT)

(GIBCO, Grand Island, N.Y.), and 15% Fetal Bovine Sera

(FBS)(GIBCO, Grand Island, N.Y.).

The fused cells were

delivered to 96 well plates previously seeded with a feeder
layer of Balb/c thymocytes (lx 106 cells per w e l l ) .

During

the first week following fusion the cells were fed twice
with 100 ul RPMI supplemented with Hypozanthine-AminopterinThymidine (HAT)

(GIBCO, Grand Island, New York) and FBS.

At

the end of the first week, cells were fed with 100 ul RPMI
supplemented with HT and FBS.

Medium supplemented with HT

was used to feed the cells until the cells were cloned by
limiting dilution.

At the end of the second week, culture

supernatant fluids from each well which contained a
developing hybridoma was screened for antibody production by
both whole cell and LPS ELISA.

Hybridomas in wells that

tested positive for the desired antibody were cloned by
limiting dilution until a stable cell line was generated.
Whole Cell E1ISA

Vibrio cells, grown on alkaline peptone

agar at 30° C overnight, were harvested in .05 M NaHC03NaC0 3 coupling buffer, pH 9.6.

The cells were washed one

time in coupling buffer and suspended to 3 x 108 cells per
ml.

A 50 ul aliquot was delivered to each well of a 96 well

polystyrene ELISA plate (Immunlon II; Dynatech Laboratories,
Inc., Alexandria, Va.).

The plates were incubated

overnight, uncovered, at 37° C.

The wells were blocked by
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the addition of 200 ul of 2% BSA in Tris-EDTA-NaCl buffer
(TEN)(0.05 M TRIS-HCL, 0.001 M EDTA, 0.15 M NaCl,pH 7.2) for
30 minutes at 37° C.

The wells were washed one time with

TEN buffer and then 50 ul of test fluid or control sera was
added to each well and incubated at 37° C for 30 minutes.
The wells were washed one time to remove unbound antibody
and 50 ul of anti-mouse Ig-phosphatase conjugate (Sigma
Chemical Company, St. Louis, Mo.) diluted 1:200 in TEN
buffer supplemented with 2% BSA was added to each well.

The

plates were incubated for 30 minutes at 37° C, and each well
was washed five times with TEN buffer.
patted completely dry, and

200

ul of

1

The plates were
mg per ml phosphatase

substrate (o-nitrophenyl phosphate, Sigma Chemical Company,
St. Louis, Mo.) diluted in diethanolamine buffer (97 ml
diethanolamine,

100 mg MgCl 2 .6H20, 0.2 mg NaN 3 per liter) pH

9.8 was added to each well.

The plates were incubated at

37° C for 30 minutes and absorbance was read at 405 nm with
a manual ELISA reader (Bio-Tek, Inc.).
which exhibited an absorbance of

0.2

Culture supernates

or greater were

considered positive.
LPS ELISA.

The LPS ELISA's were done using the protocol

described above with the following modifications.
Detoxified LPS, diluted to 50 ug per ml in PBS, pH 7.3, was
used as antigen (both PS and lipid moieties were present).
Polyvinyl chloride microtiter plates (Dynatech Laboratories
Inc., Alexandria, Va.) were coated with 50 ul of LPS (2.5 ug
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LPS per well) and Incubated at 37° C overnight to dry.

The

protocol stated above was followed using either PBS or TEN
buffer as the wash solution.

Results
Polyclonal V. vulnificus antiserum raised in rabbits
immunized with whole cell vaccines produced slide
agglutination patterns that were non-reciprocal and non
specific (Table 1).

These findings were consistent with

reports in the literature (Shimada and Sakazaki 1984) and
our previous experience*

The two traditional methods used

to remove cross-reactivity from polyclonal serum are
dilution and absorption.

Polyclonal antiserum produced in

rabbits against V. vulnificus exhibited low agglutination
titers, usually < 1280 by Passive Hemagglutination or <320
by O-antigen agglutination.

Because of the low titers,

dilution of the sera did not eliminate cross-reactions.
When these sera were used in slide agglutination tests a 1:5
dilution of polyclonal antiserum results in the loss of
serological activity.
Anti-LPS activity was eluted from amino-hexyl
sepharose-LPS affinity columns.

Direct bacterial slide

agglutinations tests were done with the affinity purified
anti-LPS antibody with both formalinized and live Vibrio
cell suspensions as antigen.

In most instances, killed

bacteria showed stronger agglutination patterns than did
live organisms (Table 2).

The number of cross-reactions was

reduced in all five sera tested and eliminated in the case
of W 1 0 0 8 ,

however, some non-specific agglutination was

still present.
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TABLE 1.

Agglutination patterns for 5 anti-V. vulnificus

sera raised in rabbits immunized with formalinized whole
cell vaccines and tested against vaccine strains.

Vaccine Strains
Suspended in FPBS

anti-

anti-

anti-

anti-

anti-

1002

1003

1005

1006

1008

Vvl002

++

+

+

+

+

W1003

+

++

+

0

++

W1005

0

++

++

++

++

W1006

0

++

++

++

++

W1008

0

0

0

++

++

VvATCC 27562

0

++

++

++

++

++= Immediately discernable agglutination
+= Weak/Delayed agglutination
0= No discernable reaction
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TABLE 2. Slide agglutination patterns for five affinity
purified anti-V. vulnificus-PS sera.

Antibody eluted from

AH-Sepharose armed with PS extracted from each of the
vaccine strains.

Test antigen was whole cells suspended in

0.3% formalinized PBS

(fixed) and saline (live).

vaccine anti- 1 0 0 2 anti- 1003 anti- 1005 anti- 1006 anti -1008
strains

F

L

F

L

F

L

F

L

F

L

1002

++

++

0

0

0

0

0

0

0

0

W1003

++

0

++

++

0

0

0

0

0

0

VV1005

0

+

++

++

++

+

++

++

0

0

Vvl006

0

0

++

0

++

0

++

++

0

0

W1008

0

+

0

0

0

0

0

0

++

++

VvATCC

++

0

++

0

++

+

0

0

0

0

W

++= Immediately discernable agglutination
+= Weak/Delayed agglutination
0= No discernable reaction
F= Fixed
L= Live

69
These findings (Table 2) were used as the basis for
selection of V. vulnificus strains to be used to
produce monoclonal antibodies.

The cross-agglutination

reactions between a n t i - W 1 0 0 5 and anti-Vvl006 was strong and
reciprocal, and as a result, only strain Vvl005 was selected
as a candidate for monoclonal antibody production.
Agglutination patterns of strains Vvl002 and Vvl008
suggested that these two isolates represented distinct LPS
serovar which were distinct from Vvl005.
Hybridoma clones were screened by both a whole cell and
LPS ELISA.

Both approaches were tested for two reasons.

First, the Westphal LPS extraction procedure may have
altered or degraded LPS epitopes.

It was prudent therefore

to test culture supernates clones reactivity not only
against purified LPS but, also against whole cells (native
LPS ) .

Second, LPS reactive Mab might not be the only

activity of value.

It would be possible to identify clones

that had strong reactivity against whole cells but, were
non-reactive against LPS.

Such Mab's might recognize

epitopes on other cell surface antigens that may have been
responsible for cross reactivity observed with polyclonal
antiserum.

In the LPS ELISA, both the polysaccharide and

the lipid portion of the LPS molecule were present which
provided the opportunity to identify anti-Lipid A or anti
core oligosaccharide Mab's, which should react with each
LPS preparation.

No activity specific for lipid A or core-

TABLE 3. Serological specificity of monoclonal antibodies
versus polyclonal antisera for LPS (0--serovar specific)
antigens.
V. vulnificus
Anti-Vvl002
LPS
Polyclonal Monoclonal
Vv 846
VvlOOO
W1001
W 1002
Vvl003
W1004
W1005
Vvl006
W1007
VV1008
Vvl009
VvlOlO
W1012
W1013
W1014
W1015
WE4125
VvATCC 27562
a
a

Qa Qa
o o
1! II
+ +
+

0.2
1.0

0

0

0

0

+
++
++
++
+

0

++
0
0
0

0

0

+
+

++

0

+
+
+
+
+
+
+
@ 405 nm.
@ 405 nm.

0
0
0
0
0
0
0

++
0

Anti- 1005
Polyclonal Monoclonal
++
++
++
++
+
+
++
++
++
++
+
++
+
+
+
+
++
+

0
0
0
0
0
0

++
++
0
0
0
0
0
0
0
0
0

++

•
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oligosaccharide was detected.
Lipopolysaccharide ELISA titrations were done using
both polyclonal sera and Mab.

These experiments showed that

unique LPS epitopes could be identified and that Mab did not
exhibit the cross reactions (Table 3).
Six different LPS serovars have been identified by LPS
ELISA within the 16 V. vulnificus isolates examined.
Monoclonal antibodies have been produced that react with
five of these six serovars (Table 4).

Monoclonal antibody

was produced that reacted with LPS extracted from V. damsela
and V. hollisae. which were non-reactive with the V.
vulnificus L P S 's .
The V. vulnificus LPS serovars identified, thus far,
have been assigned numbers 1 through

6

predicated on ELISA

titers run with either monoclonal or affinity purified antiLPS antibodies (Table 5).
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TABLE 4. Hybridomas producing V. vulnificus lipopolysaccharide-specific monoclonal antibody.
Determined by LPS
ELISA of cell culture supernates.
LPS

SM-3

W 1000
0c
VvlOOl
++d
Vvl002
0
Vvl003
0
Vvl004
0
Vvl005
0
Vvl006
0
Vvl007
0
0
W1008
VV1009
0
W1010
0
VV1012
0
0
W1013
W1015
0
VvE4125
0
VvATCCa
0
V.damsela 0
V.hollisaeO
Negativeb 0

SM-1

SM-29

Anti-LPS Hybridomas
SM-11
SM-3 9
SM-15

SM-19

0

0

0

0

0

0

0

0
0

0

0

0

++

0
0

0

0

0

0

0

0

0

0

0

0
0

++

0

0

0

0

0
0

0
0

0

0
0

++
++

0
0

0
0

0

++
0

0

0

0
0

0

0

0

0

0

0

++

0

0

0

0

0

0

0

0

0

0
0

0

0

0

++

0
0

0

0

0

0
0

0

0

0

0

++

0

0

0

0

0

0

0

++

0

0

0

0

0

++

0

0

0
0

0

0

0

0

++

0

0

0

0

0

0

®= V. vulnificus ATCC type strain #27562
= V. carchariae LPS ( Vibrio species not associated with
human disease)
*= Negative LPS ELISA, O.D.< 0.2
d= Positive LPS ELISA, O.D.> 1.0
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TABLE 5.

Proposed serological varieties of V. vulnificus

based on lipopolysaccharide specific monoclonal antibodies.

Serovar

MAb

Strain

Incidence

%

1

SM-11

Vvl005

3/16

19

2

SM-3

VvlOOl

1/16

6

3

SM-1

W1002

2/16

12

4

SM-29

W1004

1/16

6

5

SM-3 9

W1009

1/16

6

6a

N. A.

VV1008

2/16

12b

a= Tentative serovar based on affinity purified polyclonal
b= 61% of Louisiana V. vulnificus strains tested fall into
these six LPS serovars.
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Whole cell preparations of the translucent and opaque
phenotypes of V. vulnificus

and their respective LPSs were

tested by both LPS and whole cell ELISA to determine if the
presence of capsule (more abundant in opaque strains)
interfere with the serological activity of anti-LPS.

V.

vulnificus isolate 1005 was tested because opaque and
translucent cells and polyclonal antisera and Mab were
available.

The highest dilution that produced a 0.2

absorbance or greater was read as the endpoint (Table

6

).

The presence of capsule interfered with the activity of both
polyclonal antisera and Mabs.

A sixteen-fold reduction in

the activity of Mab SM-11 against whole opaque cells as
compared to translucent cells was observed.

There was no

difference in the LPS ELISA titers for LPS extracted from
opaque and translucent cells.
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TABLE

6

. ELISA titers for opaque and translucent V.

vulnificus whole cells and LPS extracted from opaque and
translucent V. vulnificus cells vs. polyclonal and
monoclonal sera.

V. vulnificus 1005

Colony Type

Rabbit antiserum

1005-0

1005—T

Mab

Antigen

1005

SM-11

Opaque

LPS

32,000

64,000

256,000

4,000

Translucent

LPS

32,000

64,000

256,000

4,000

Opaque

Cells

8,000

8,000

8,000

4,000

Translucent

Cells

16,000

16,000

16,000

64,000
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Discussion
Polyclonal antisera was found unacceptable for the
serological typing of V. vulnificus.

Affinity purified

polyvalent anti-LPS did not exhibit the magnitude of cross
reactions that were seen with the whole antiserum (Tables 1
& 2 ).

It was possible to use affinity purified anti-LPS

sera to select V. vulnificus strains to be used to produce
monoclonal antibodies.

Affinity purification worked well

for some anti-LPS preparations.

Polyclonal anti-Vvl008

serum which reacted with all strains tested was rendered
specific for 1008 cells when anti-1008 was affinity
purified.

Because antisera raised to V. vulnificus usually

exhibit low anti-LPS PHA titers, with PHA titers < 1280
compared to titers of 160,000 obtained with V. cholerae Non01 (Adams and Siebeling 1984), the serum could not be
diluted to reduce non-specific cross-reactions.
Monoclonal antibodies which react with LPS can be used
to serotype either the opaque or translucent phenotypes of
V. vulnificus

(Table 5).

ELISA titers suggest that the LPS

epitopes are more readily accessible on the surface of the
translucent cell than on the opaque cell.

This finding

suggests that the capsule or slime layer present on the
opaque cell may block access of the monoclonal antibody to
the LPS.
The five anti-V. vulnificus LPS Mab's produced
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recognize only 50% of the 16 V. vulnificus isolates tested.
These results indicate that there is more heterogeneity in
V. vulnificus LPS than was previously reported (Shimada and
Sakazaki 1984).

Since the majority of the isolates used in

this study were recovered in Louisiana there maybe a greater
distribution of LPS antigens than these findings indicate.
Preliminary results obtained with Mab reactive with LPS from
V. damsela and V. hollisae did not react with LPS prepared
from V. vulnificus, which suggests that these two marine
Vibrios express unique LPS 0 determinates.

Due to the small

number of strains tested no accurate correlation between LPS
antigens and virulence can be made.
Vibrio vulnificus isolates can be serotyped by
utilizing LPS specific Mab.

To be of value in

epidemiological and environmental studies, the typing scheme
will have to be expanded to completely cover the possible
LPS serovars presented by this organism.
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